Background: Currently, fungal diseases of humans are among the most problematic illnesses isrnthe result of an increase in opportunistic fungal infections caused by rise in the number ofrnimmune-compromised patients. Particularly, yeasts are the most common cause of fungalrninfections leading to a range superficial type to life-threatening invasive infections. The aim ofrnthis study is to determine species distribution and antifungal susceptibility profile of yeastsrnparticularly of Candida species recovered from different clinical samples. rnMethod: A cross sectional study was conducted from January 01, 2018 â€“September 30, 2018 inAddis Ababa, Arsho laboratory. Oropharengial swabs ,nail scrapings, sputum, corneal scrapings,rnand vaginal swabs were collected from patients with signs and symptoms of i nfections.Identification and antifungal susceptibility testing was performed by using YST and AST-YS07rncard through VITEK 2 compact system. Data was entered and analyzed using SPSS version 20. rnResult: A total of 209 yeasts were recovered of which 49.8% were Candida albicans, 43.1%were non-albicans candida species and 7.2% were yeasts other than Candida species. Thecurrent study, eighteen (18) different types of yeast species were identified from different clinicalsamples. All recognized yeast considered as a causative agent of fungal infection in previouslyrnreported data in worldwide. Entire isolates of 85.6 %, 99.4 %, 98.8 %, 98.8 %, 86.2 % werernsusceptible to fluconazole,Voriconazole,micafungin,Caspofungin , and flucytosine, respectively.Candida albicans isolates were 100% susceptible to voriconazole, caspofungin, and micafungin. As of whole isolates were showed 1.6 % cross-resistance and 8.6 % multi drug-resistance. rnConclusion: C. albicans remaining the predominant species, but the emergence of non-albicansCandida and other than candida species have increased .In vitro-resistance to fluconazole,voriconazole and flucytosine was rare among C. albicans.However, an increase of nonsusceptibilityrnwasrnobservedrnamongrnC.rnkrusiernandrnC.rugosarnforrnfluconazolernandrnflucytosine.rnThus,morernstudiesrnonrnCandidarnprevalencernandrndrugrnsusceptibilityrnarernneededrnthroughoutrncountry.